99 related articles for article (PubMed ID: 11448050)
1. Acrylic resins as rate-controlling membranes in novel formulation of a nine-day 17beta-estradiol transdermal delivery system: in vitro and release modifier effect evaluation.
Rafiee-Tehrani M; Safaii-Nikui N; Peteriet H; Beckert T
Drug Dev Ind Pharm; 2001 May; 27(5):431-7. PubMed ID: 11448050
[TBL] [Abstract][Full Text] [Related]
2. Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion.
Gondaliya D; Pundarikakshudu K
AAPS PharmSciTech; 2003; 4(1):E3. PubMed ID: 12916913
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of mathematical models describing drug release from estradiol transdermal systems.
Costa P; Sousa Lobo JM
Drug Dev Ind Pharm; 2003 Jan; 29(1):89-97. PubMed ID: 12602496
[TBL] [Abstract][Full Text] [Related]
4. Crystallization of beta-estradiol in an acrylic transdermal drug delivery system.
Variankaval NE; Jacob KI; Dinh SM
J Biomed Mater Res; 1999 Mar; 44(4):397-406. PubMed ID: 10397943
[TBL] [Abstract][Full Text] [Related]
5. Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems.
Lee KE; Choi YJ; Oh BR; Chun IK; Gwak HS
Int J Pharm; 2013 Nov; 456(2):432-6. PubMed ID: 24008082
[TBL] [Abstract][Full Text] [Related]
6. Novel biomaterial for transdermal application: in vitro and in vivo characterization.
Mundada AS; Avari JG
Drug Deliv; 2011 Aug; 18(6):424-31. PubMed ID: 21554152
[TBL] [Abstract][Full Text] [Related]
7. In-vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS.
Funke AP; Günther C; Müller RH; Lipp R
J Control Release; 2002 Jul; 82(1):63-70. PubMed ID: 12106977
[TBL] [Abstract][Full Text] [Related]
8. The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin.
Choi A; Gang H; Chun I; Gwak H
Int J Pharm; 2008 Jun; 357(1-2):126-31. PubMed ID: 18329198
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of ion-pair releasing from acrylic pressure sensitive adhesive containing carboxyl group: Roles of doubly ionic hydrogen bond in the controlled release process of bisoprolol ion-pair.
Zhao H; Liu C; Yang D; Wan X; Shang R; Quan P; Fang L
J Control Release; 2018 Nov; 289():146-157. PubMed ID: 30268589
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
Yang Z; Teng Y; Wang H; Hou H
Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
[TBL] [Abstract][Full Text] [Related]
11. Matrix type transdermal therapeutic system containing captopril: formulation optimization, in vitro and ex vivo characterization.
Kerimoğlu O; Keskin E; Dortunç B; Anah S
Acta Pol Pharm; 2013; 70(2):291-300. PubMed ID: 23614285
[TBL] [Abstract][Full Text] [Related]
12. Eudragits: role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol.
Kotiyan PN; Vavia PR
Eur J Pharm Biopharm; 2001 Sep; 52(2):173-80. PubMed ID: 11522483
[TBL] [Abstract][Full Text] [Related]
13. Design of antihistaminic transdermal films based on alginate-chitosan polyelectrolyte complexes: characterization and permeation studies.
Lefnaoui S; Moulai-Mostefa N; Yahoum MM; Gasmi SN
Drug Dev Ind Pharm; 2018 Mar; 44(3):432-443. PubMed ID: 29098871
[TBL] [Abstract][Full Text] [Related]
14. Transdermal dual-controlled delivery of contraceptive drugs: formulation development, in vitro and in vivo evaluations, and clinical performance.
Chien YW; Chien TY; Bagdon RE; Huang YC; Bierman RH
Pharm Res; 1989 Dec; 6(12):1000-10. PubMed ID: 2516312
[TBL] [Abstract][Full Text] [Related]
15. Preparation and characterization of metoprolol controlled-release solid dispersions.
Varshosaz J; Faghihian H; Rastgoo K
Drug Deliv; 2006; 13(4):295-302. PubMed ID: 16766471
[TBL] [Abstract][Full Text] [Related]
16. Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems.
Babu RJ; Pandit JK
Int J Pharm; 2005 Jan; 288(2):325-34. PubMed ID: 15620873
[TBL] [Abstract][Full Text] [Related]
17. [Development and in vitro evaluation of estradiol transdermal film-forming spray].
Yu ZW; Liang Y; Liang WQ
Yao Xue Xue Bao; 2013 May; 48(5):746-51. PubMed ID: 23888700
[TBL] [Abstract][Full Text] [Related]
18. Development of a membrane-controlled transdermal therapeutic system containing isosorbide dinitrate.
Ocak F; Ağabeyoğlu I
Int J Pharm; 1999 Apr; 180(2):177-83. PubMed ID: 10370188
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems.
Yang Y; Manda P; Pavurala N; Khan MA; Krishnaiah YS
J Control Release; 2015 Jul; 210():58-66. PubMed ID: 25979329
[TBL] [Abstract][Full Text] [Related]
20. Formulation and evaluation of ubidecarenone transdermal delivery systems.
Jung SY; Kang EY; Choi YJ; Chun IK; Lee BK; Gwak HS
Drug Dev Ind Pharm; 2009 Sep; 35(9):1029-34. PubMed ID: 19365779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
